CC
ALLO icon

Corton Capital’s Allogene Therapeutics ALLO Stock Holding History

Corton Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,628
Closed -$40K – 566
2023
Q3 		$40K Sell
12,628
-13,957
-52% -$61.2K 0.02% 411
2023
Q2 		$132K Sell
26,585
-6,565
-20% -$35.5K 0.06% 381
2023
Q1 		$164K Sell
33,150
-958
-3% -$6.14K 0.11% 261
2022
Q4 		$215K Buy
34,108
+11,392
+50% +$105K 0.18% 201
2022
Q3 		$245K Sell
22,716
-11,620
-34% -$158K 0.3% 149
2022
Q2 		$391K Buy
34,336
+12,040
+54% +$107K 0.37% 90
2022
Q1 		$203K Sell
22,296
-4,045
-15% -$42.1K 0.09% 356
2021
Q4 		$393K Buy
+26,341
New +$465K 0.17% 122

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Corton Capital's ALLO Position: Q4 2023 in Review

Corton Capital sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 12,628 shares — an estimated $40K sold.

Corton Capital first reported a position in ALLO in Q4 2021 and held it in 8 quarters. The position peaked at $393K in Q4 2021. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

  • Corton Capital reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Corton Capital sold 12,628 Allogene Therapeutics shares in Q4 2023, an estimated $40K.
  • Corton Capital first reported a position in Allogene Therapeutics in Q4 2021 and held it in 8 quarters.
  • Corton Capital's Allogene Therapeutics position peaked at $393K in Q4 2021.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on Corton Capital's 13F filing for Q4 2023, filed 14 Feb 2024.